NAS:MYOK (USA) Also trade in: Germany Mexico

MyoKardia Inc

$ 49.82 0 (0%)
Volume: 195,605 Avg Vol (1m): 392,259
Market Cap $: 2.30 Bil Enterprise Value $: 1.74 Bil
P/E (TTM): 0.00 P/B: 3.32
Earnings Power Value 1.06
Net Current Asset Value 13.13
Tangible Book 15.11
Projected FCF 0
Median P/S Value 24.43
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 9/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 220.96
Cash-To-Debt range over the past 10 years
Min: 220.96, Med: 10000, Max: 10000
Current: 220.96
220.96
10000
Equity-to-Asset 0.91
Equity-to-Asset range over the past 10 years
Min: 0.31, Med: 0.82, Max: 0.91
Current: 0.91
0.31
0.91
Debt-to-EBITDA -0.03
Debt-to-EBITDA range over the past 10 years
Min: -0.03, Med: 0, Max: 0
Current: -0.03
-0.03
0
Interest Coverage No Debt
N/A
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 44.13
DISTRESS
GREY
SAFE
Beneish M-Score -1.41
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -505.84%
WACC 9.25%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -282.47
Operating Margin range over the past 10 years
Min: -512.73, Med: -219.47, Max: -25.1
Current: -282.47
-512.73
-25.1
Net Margin % -260.29
Net Margin range over the past 10 years
Min: -498.25, Med: -201.73, Max: -24.73
Current: -260.29
-498.25
-24.73
ROE % -22.21
ROE range over the past 10 years
Min: -652.31, Med: -41.14, Max: -8.68
Current: -22.21
-652.31
-8.68
ROA % -20.08
ROA range over the past 10 years
Min: -270.04, Med: -25.81, Max: -6.53
Current: -20.08
-270.04
-6.53
ROC (Joel Greenblatt) % -1754.04
ROC (Joel Greenblatt) range over the past 10 years
Min: -1987.03, Med: -803.9, Max: -382.88
Current: -1754.04
-1987.03
-382.88
3-Year Total Revenue Growth Rate 33.20
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -27.1, Max: -1.2
Current: -27.1
0
-1.2
3-Year Total EBITDA Growth Rate -48.00
3-Year EBITDA Growth Rate range over the past 10 years
Min: -20.2, Med: 19, Max: 24.7
Current: 19
-20.2
24.7
3-Year EPS w/o NRI Growth Rate 26.80
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -4.2, Max: 26.8
Current: 26.8
0
26.8

» MYOK's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:MYOK

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:XLRN NAS:EDIT XKRX:095700 NAS:SPPI NAS:RXDX NYSE:CBM NAS:AIMT NAS:ESPR BOM:539268 NAS:SGMO SZSE:002653 SZSE:002287 NAS:CORT NAS:INSM NAS:ARNA NAS:INVA NAS:MDGL XKRX:005250 NAS:IMGN NAS:PTLA
Traded in other countries 9MK.Germany
Address 333 Allerton Avenue, South San Francisco, CA, USA, 94080
MyoKardia Inc is a US-based clinical-stage biopharmaceutical company which is engaged in discovering, developing and commercializing targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The company mainly focuses on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It uses its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy—hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy. The company's products include MYK-461 s an orally administered small molecule to reduce excessive cardiac muscle contractility leading to HCM.

Ratios

Current vs industry vs history
PB Ratio 3.32
PB Ratio range over the past 10 years
Min: 1.95, Med: 4.96, Max: 11.52
Current: 3.32
1.95
11.52
PS Ratio 69.77
PS Ratio range over the past 10 years
Min: 8, Med: 34.21, Max: 162.61
Current: 69.77
8
162.61
EV-to-EBIT -18.33
EV-to-EBIT range over the past 10 years
Min: -55.8, Med: -17.7, Max: -3.1
Current: -18.33
-55.8
-3.1
EV-to-EBITDA -18.68
EV-to-EBITDA range over the past 10 years
Min: -58.9, Med: -18.5, Max: -3.2
Current: -18.68
-58.9
-3.2
EV-to-Revenue 51.86
EV-to-Revenue range over the past 10 years
Min: 4.9, Med: 29.9, Max: 153.5
Current: 51.86
4.9
153.5
Current Ratio 18.00
Current Ratio range over the past 10 years
Min: 0.94, Med: 5.41, Max: 18
Current: 18
0.94
18
Quick Ratio 18.00
Quick Ratio range over the past 10 years
Min: 0.94, Med: 5.41, Max: 18
Current: 18
0.94
18

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -12.40
3-Year Share Buyback Rate range over the past 10 years
Min: -29.8, Med: -24.2, Max: -12.4
Current: -12.4
-29.8
-12.4

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.30
Price-to-Tangible-Book range over the past 10 years
Min: 2.8, Med: 4.75, Max: 8.07
Current: 3.3
2.8
8.07
Price-to-Median-PS-Value 2.04
Price-to-Median-PS-Value range over the past 10 years
Min: 0.27, Med: 0.95, Max: 3.57
Current: 2.04
0.27
3.57
Earnings Yield (Joel Greenblatt) % -5.46
Earnings Yield (Greenblatt) range over the past 10 years
Min: -32.6, Med: -5.7, Max: -1.8
Current: -5.46
-32.6
-1.8

More Statistics

Revenue (TTM) (Mil) $ 33.56
EPS (TTM) $ -2.19
Beta 1.2
Volatility % 47.96
52-Week Range $ 39.01 - 67.79
Shares Outstanding (Mil) 35.81

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y